My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

18.81 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 4, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Cleveland-Cliffs, United States Steel, monday.com And Other Big Stocks Moving Higher On Monday ↗

August 14, 2023

U.S. stocks traded higher, with the Nasdaq Composite gaining around 100 points on Monday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023

August 09, 2023

From Summit Therapeutics Inc.

Via Business Wire

Summit Therapeutics to Host Q2 2023 Financial Results & Operational Progress Call on August 9, 2023

August 02, 2023

From Summit Therapeutics Inc.

Via Business Wire

AlloVir, DigitalOcean And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

June 22, 2023

U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. AlloVir, Inc. (NASDAQ: ALVR) shares dipped 24.1% to $3.74 in pre-market...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

June 20, 2023

Via Benzinga

Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023

June 04, 2023

From Summit Therapeutics Inc.

Via Business Wire

Ivonescimab Updated Data to be Featured at ASCO 2023

June 01, 2023

From Summit Therapeutics Inc.

Via Business Wire

Why Shares of Summit Therapeutics Slumped on Tuesday ↗

May 16, 2023

The company's shares have been falling since it announced earnings late last week.

Via The Motley Fool

Why RH Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 16, 2023

Gainers GD Culture Group Limited (NASDAQ: GDC) shares climbed 121.9% to $9.63 after gaining over 8% on Monday. GD Culture recently announced an $11.55 million registered direct offering.

Via Benzinga

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023

May 11, 2023

From Summit Therapeutics Inc.

Via Business Wire

Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)

May 09, 2023

From Summit Therapeutics Inc.

Via Business Wire

Why Shares of Summit Therapeutics Soared This Week ↗

May 05, 2023

Summit Therapeutics advanced its lead therapy into two phase 3 trials to treat non-small cell lung cancer.

Via The Motley Fool

Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (SMT112)

May 03, 2023

From Summit Therapeutics Inc.

Via Business Wire

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Summit Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm

March 21, 2023

From Schall Law Firm

Via Business Wire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Summit Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm

March 20, 2023

From The Schall Law Firm

Via Business Wire

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022

March 09, 2023

From Summit Therapeutics Inc.

Via Business Wire

Over $395M Bet On This Biotechnology Stock? Check Out These 4 Penny Stocks Insiders Are Buying ↗

March 09, 2023

The Dow Jones closed lower on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks...

Via Benzinga

Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering

March 03, 2023

From Summit Therapeutics Inc.

Via Business Wire

Macy's, Big Lots, Sprouts Farmers Market And Other Big Stocks Moving Higher On Thursday ↗

March 02, 2023

U.S. stocks traded mixed, with the Dow Jones gaining around 100 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Workday, AdaptHealth And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

February 28, 2023

U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. AdaptHealth Corp (NASDAQ: AHCO) shares dipped 18.3% to $17.95 in...

Via Benzinga

Summit Therapeutics’ Rights Offering Nearing Expiration Date

February 23, 2023

From Summit Therapeutics Inc.

Via Business Wire

Acurx is Setting a High Bar for New Treatments in C. diff ↗

February 14, 2023

A New Gold Standard for C. diff Therapy Could be in the Offing; Next Data Release Expected in 2Q23

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

February 07, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

February 03, 2023

Via Benzinga

Ford, Atlassian, Amazon And Other Big Stocks Moving Lower On Friday ↗

February 03, 2023

U.S. stocks traded lower, with the Dow Jones dropping over 100 points on Friday. Here are some big stocks recording losses in today’s session.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

February 03, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

February 03, 2023

Good morning! It's time to start the final day of trading this week with a look at the biggest pre-market stock movers for Friday!

Via InvestorPlace

Why Alphabet And Amazon Are Trading Lower; Here Are 20 Stocks Moving Premarket ↗

February 03, 2023

Gainers Nordstrom Inc. (NYSE: JWN) shares surged 29.56% to $27.39 in pre-market trading after activist investor Ryan Cohen took a stake in the company and announced he is planning to urge a board...

Via Benzinga

Summit Therapeutics Announces Timing for Rights Offering for Up to $500 Million

January 30, 2023

From Summit Therapeutics Inc.

Via Business Wire

Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug ↗

January 28, 2023

Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion,...

Via Talk Markets

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.